LTBR-enhanced CAR T-cell therapy for relapsed or refractory B‑cell lymphoma
LTBR CARs as next-generation therapies for R/R lymphoma
The team will make CAR T-cells that carry LTBR to help people with relapsed or refractory diffuse large B‑cell lymphoma get stronger, longer-lasting responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Genome Center NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11311797 on NIH RePORTER |
What this research studies
You would be contributing blood or tumor samples so researchers can compare immune cell activity in newly diagnosed versus relapsed DLBCL. They will use single-cell profiling and lab tests to measure T-cell activation, exhaustion, and supporting myeloid cells. Scientists will engineer patients' autologous CAR T-cells to express LTBR and test those cells in functional assays and animal models to see if they kill lymphoma more effectively. If the lab and preclinical results are promising, the work could lead to clinical testing of LTBR-enhanced CAR T therapies.
Who could benefit from this research
Good fit: Adults with relapsed or refractory diffuse large B‑cell lymphoma, particularly those eligible for CD19-directed CAR T-cell therapy or willing to donate blood or tumor samples, would be the ideal candidates.
Not a fit: People with non–B‑cell cancers, those whose DLBCL is controlled by first-line treatment, or those ineligible for CAR T procedures would likely not benefit directly from this work.
Why it matters
Potential benefit: This approach could increase the number of people who get long-term remissions and extend survival after relapsed DLBCL.
How similar studies have performed: CD19-directed CAR T therapies have cured some patients with relapsed DLBCL but only about 35% achieve durable remission, and LTBR modification is a novel strategy that has shown promise in preclinical lab and animal studies but not yet in humans.
Where this research is happening
New York, United States
- New York Genome Center — New York, United States (Active)
Researchers
- Principal investigator: Sanjana, Neville — New York Genome Center
- Study coordinator: Sanjana, Neville
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.